adb-chminaca adb-chminaca adb-chminaca (also known as mab-chminaca) is an indazole-based synthetic cannabinoid. it is a potent agonist of the cb1 receptor with a binding affinity of ki = 0.289 nm and was originally developed by pfizer in 2009 as an analgesic medication. it was identified in cannabinoid blends in japan in early 2015. adb-chminacalegal statuslegal status ca: schedule ii de: anlage ii (authorized trade only, not prescriptible) uk: class b us: schedule i illegal in singapore, sweden, switzerland identifiers iupac name n--1-(cyclohexylmethyl)indazole-3-carboxamide cas number1185887-13-1 ypubchem cid68894304chemspider48059556uniisl4c60689mchemical and physical dataformulac21h30n4o2molar mass370.497 g·mol−13d model (jsmol)interactive image smiles cc(c)(c)(nc(=o)c1nn(cc2ccccc2)c3ccccc13)c(n)=o inchi inchi=1s/c21h30n4o2/c1-21(2,3)18(19(22)26)23-20(27)17-15-11-7-8-12-16(15)25(24-17)13-14-9-5-4-6-10-14/h7-8,11-12,14,18h,4-6,9-10,13h2,1-3h3,(h2,22,26)(h,23,27)/t18-/m1/s1key:zwccsiubhczkoy-gosisdbhsa-n side effects there have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid. legal status in the united states, adb-chminaca is a schedule i controlled substance. prior to its listing at the federal level in 2018, louisiana placed adb-chminaca on its schedule i list by emergency scheduling in 2014. sweden's public health agency suggested to classify adb-chminaca as hazardous substance on november 10, 2014. adb-chminaca is listed in the fifth schedule of the misuse of drugs act (mda) and therefore illegal in singapore as of may 2015. adb-chminaca is illegal in switzerland as of december 2015. metabolism ten adb-chminaca major metabolites were identified in several incubations with cryopreserved human hepatocytes. most transformations occurred at the cyclohexylmethyl tail of the compound.